98%
921
2 minutes
20
Purpose: The maximal dose for partial breast irradiation (PBI) with stereotactic body radiation therapy for definitive local therapy of nonmetastatic breast cancer has not been established. Here we evaluate the maximal achievable coverage of the planning target volume suitable for PBI without violating organs-at-risk constraints.
Methods And Materials: Planning computed tomography scans of 22 patients with pulmonary or cardiac risk factors and left-sided disease in prone and supine position (sp) were obtained. Plans for PBI in 5 fractions were generated according to the Guidelines of the American Society for Radiation Oncology. Maximum tolerated dose (MTD) was defined when the dose reached any constraint of a neighboring organ based on recommendations of the American Association for Physics in Medicine.
Results: Mean MTD was 45.9 ± 3.9 Gy (range, 38.8-53.9) in sp and 46.1 ±3.2 Gy (range, 37.3-53.9) in prone position (pp), respectively. The MTD was ≥44.3 Gy in sp and ≥44.8 Gy in pp in 95% of patients. Fat tissue was the dose limiting structure in 11 of 22 patients in sp and 15 of 22 in pp. D to the fat tissue reached 40.0 Gy (±3.3 Gy) in sp and pp. Skin was the dose limiting structure in 7 of 22 patients in sp and in 6 of 22 in pp. D to the skin was 30.5 Gy (±7.4 Gy) in sp and 31.0 Gy (±7.0 Gy) in pp ( = .8). Ribs were dose limiting in 4 of 22 patients in sp and in 1 of 22 in pp. D to the ribs was 31.4 Gy (±9.5 Gy) in sp and 21.4 Gy (±11.0 Gy) in pp ( < .01). D to the intraventricular artery was 3.4 Gy (±3.1 Gy) in sp and 7.5 Gy (±5.7 Gy) in pp ( < .01).
Conclusions: For definitive stereotactic body radiation therapy for early-stage breast cancer, we propose a dose escalation starting with 45 Gy in 5 fractions to be tested in a clinical trial. Prone position is advised for tumors close to the thoracic cage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142499 | PMC |
http://dx.doi.org/10.1016/j.adro.2025.101775 | DOI Listing |
Cancer Pathog Ther
September 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27708, United States.
Background: Stereotactic body radiotherapy (SBRT) is an effective treatment for early-stage non-small cell lung cancer. However, patient breathing can affect treatment accuracy. Therefore, this study aimed to develop a bi-polar (BP) gated motion management strategy for SBRT and evaluate its feasibility geometrically and dosimetrically.
View Article and Find Full Text PDFRadiat Oncol
September 2025
Department of Breast Sarcoma and Endocrine Tumors, Karolinska University Hospital, Stockholm, Sweden.
Background: Stereotactic Body Radiotherapy (SBRT) has been proven to be a safe and effective alternative to surgery in patients with metastatic primary sarcoma. However, data describing tumor response in relation to the given radiotherapy dose is lacking. Therefore, this study aims at analyzing efficacy and dose-response relationship in a retrospective cohort.
View Article and Find Full Text PDFJ Clin Oncol
September 2025
Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Networ
J Clin Oncol
September 2025
Xingpeng Luo, MD, Bin Li, MD, and Yinglong Xi, MD, Orthopedic Treatment Center, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe State), Mengzi City, China; and Zhixiang Chen, MD, Department of Nephrology, Southern Central Hospital of Yunnan Province (The First Peo
Oncol Lett
November 2025
Department of Radiation Oncology, University Hospital Halle (Saale), D-06120 Halle (Saale), Germany.
Stereotactic body radiation therapy (SBRT) is widely used to treat inoperable non-small cell lung cancer (NSCLC). The present study analyzed the long-term (10-year) survival outcomes of patients with NSCLC treated with SBRT in a real-world setting. Patients with NSCLC treated with SBRT between 2009 and 2013 were retrospectively identified from institutional databases at the Department of Radiation Oncology, University Hospital Halle (Saale) [Halle (Saale), Germany].
View Article and Find Full Text PDF